OpenAI leads $153M round for drug-reviving startup Biossil
What's the deal? BiossilDealroom has a profile for this one. Try Dealroom → has raised $153 million in a funding round led by OpenAI. The startup, which announced the raise in September 2026, aims to bring resuscitated drugs to market.
What's the endgame? Biossil focuses on reviving shelved or abandoned drug candidates and steering them toward commercial approval. The new capital is intended to support that work.
The unicorn: The raise values the Toronto-based startup at $1 billion USD (US$158.4M), making Biossil Canada's newest unicorn. The round was led by the OpenAI Startup FundDealroom has a profile for this one. Try Dealroom →, with additional backing from Founders Fund, Quiet Capital, Modern CapitalDealroom has a profile for this one. Try Dealroom →, Golden VenturesDealroom has a profile for this one. Try Dealroom →, Panache VenturesDealroom has a profile for this one. Try Dealroom →, Duke University's endowment fund, and the Abu Dhabi Investment CouncilDealroom has a profile for this one. Try Dealroom →. The financing is structured as an all-equity raise.
The backstory: Biossil, led by co-founder and CEO Anthony Mouchantaf, exited stealth in April 2026 with $70 million USD in funding after three years spent quietly acquiring and reviving shelved drug candidates. The company buys or licenses molecules that stalled in other developers' clinical trials and advances them through its own pipeline, which currently includes trials targeting sickle cell disease, idiopathic pulmonary fibrosis, glioblastoma, breast cancer, and Alzheimer's disease. New funds will expand Biossil's clinical development capacity and back further drug-candidate acquisitions; Mouchantaf said the company is building infrastructure in the US and Canada to integrate AI and medicine "from discovery through development and into the clinic."
The signal: OpenAI backing a drug-development startup points to growing interest in applying artificial intelligence to pharmaceutical research, a field where incumbents such as Johnson & JohnsonDealroom has a profile for this one. Try Dealroom → and PfizerDealroom has a profile for this one. Try Dealroom → dominate. Other AI labs are making similar moves — Anthropic operates its own biology lab, and Cohere acquired biopharma data-processing startup Reliant AI in May to push further into healthcare.
Read more: theglobeandmail.com
Image credit: NavyMedicine
